Evidence map›Paper›PMID 30305607›Full record

ArticleCell death & disease2018

DNA-methylation-mediated silencing of miR-486-5p promotes colorectal cancer proliferation and migration through activation of PLAGL2/IGF2/β-catenin signal pathways.

Xiangxiang Liu, Xiaoxiang Chen, Kaixuan Zeng, Mu Xu, Bangshun He, Yuqin Pan, Huiling Sun, Bei Pan, Xueni Xu, Tao Xu and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 2 pooled it
3.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 2 syntheses or guidelines pooled it, 83 citations in OpenAlex.

  1. The diagnostic and prognostic value of exosomal microRNAs in lung cancer: a systematic review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Xiangxiang LiuGeneral Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, 210006, Nanjing, China.
Xiaoxiang ChenSchool of Medicine, Southeast University, 210009, Nanjing, China.
Kaixuan ZengSchool of Medicine, Southeast University, 210009, Nanjing, China.
Mu XuGeneral Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, 210006, Nanjing, China.
Bangshun HeGeneral Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, 210006, Nanjing, China.
Yuqin PanGeneral Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, 210006, Nanjing, China.
Huiling SunGeneral Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, 210006, Nanjing, China.
Bei PanGeneral Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, 210006, Nanjing, China.
Xueni XuSchool of Medicine, Southeast University, 210009, Nanjing, China.
Tao XuGeneral Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, 210006, Nanjing, China.
Xiuxiu HuSchool of Medicine, Southeast University, 210009, Nanjing, China.
Shukui WangGeneral Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, 210006, Nanjing, China. sk_wang@njmu.edu.cn.ORCID http://orcid.org/0000-0001-6972-2587
Nanjing Medical University · CNSoutheast University · CNSoutheast University · BD

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As one of the most common cancers worldwide, colorectal cancer (CRC) causes a large number of mortality annually. Aberrant expression of microRNAs (miRNAs) is significantly associated with the initiation and development of CRC. Further investigations regarding the regulatory mechanism of miRNAs is warranted. In this study, we discovered that miR-486-5p was remarkably downregulated in CRC, which partially results from higher DNA methylation in the promoter region detected by using methylation-specific PCR, bisulfite sequencing PCR, and DNA demethylation treatment. Besides, decreased miR-486-5p was obviously associated with advanced TNM stage, larger tumor size, lymphatic metastasis, and poor prognosis in CRC. Upregulated miR-486-5p inhibited the proliferation and migration of CRC through targeting PLAGL2 expression and subsequent repressing IGF/β-catenin signal pathways both in vitro and in vivo. Notably, plasma miR-486-5p expression was significantly upregulated in CRC patients and we identified plasma miR-486-5p as a novel diagnostic biomarker of CRC using receiver operating characteristic (ROC) curve analysis. Moreover, exploration in GEO dataset revealed that circulating miR-486-5p is tumor derived through being packaged into secretory exosomes. Taken together, our data demonstrated that miR-486-5p promotes colorectal cancer proliferation and migration through activation of PLAGL2/IGF2/β-catenin signal pathway, which is a promising therapeutic target of CRC treatment.

Indexed as

Animalsbeta CateninBiomarkers, TumorCell Line, TumorCell MovementCell ProliferationColorectal NeoplasmsDNA-Binding ProteinsDNA MethylationDown-RegulationExosomesFemaleGene Expression Regulation, NeoplasticGene SilencingHCT116 CellsHT29 Cellsbeta CateninBiomarkers, TumorCTNNB1 protein, humanDNA-Binding ProteinsIGF2 protein, humanInsulin-Like Growth Factor IIMicroRNAsMIRN486 microRNA, humanPLAGL2 protein, humanRNA-Binding ProteinsTranscription Factors

Identifiers

PMID30305607
PMCPMC6180105
OpenAlexW2897722799

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.